Edwards Lifesciences beats profit estimate on strength in heart devices

Edwards Lifesciences

11/02/2025 21:15

Feb 11 (Reuters) - Edwards Lifesciences  EW.N  beat
analysts' estimate for fourth-quarter profit on Tuesday, helped
by strong demand for its artificial heart valves and other
medical devices.
    Investors remain bullish on medical device makers, expecting
them to benefit from still-high demand for surgical procedures,
especially from older adults.
    Last week, larger peer Boston Scientific  BSX.N  forecast
its annual profit above Wall Street estimate, banking on steady
demand for heart devices.
    Edwards bought heart device makers JenaValve Technology and
Endotronix in deals valued at about $1.2 billion in July, as it
looks to become a pure-play structural heart company.
    The company's lead product, transcatheter aortic valve
replacement (TAVR) device, is used for minimally invasive heart
surgeries.
    Sales from the TAVR unit rose nearly 6% to $1.04 billion in
the quarter ended December 31, compared with analysts' average
estimate of $1.01 billion, according to LSEG data.
    Edwards has also been facing stiff competition for its TAVR
devices from Abbott  ABT.N , Boston Scientific and Medtronic
 MDT.N .
    The company expects its first-quarter adjusted profit to be
between 58 cents and 64 cents, compared with the estimate of 59
cents.
    On an adjusted basis, California-based Edwards earned 59
cents per share for the fourth quarter, beating the estimate of
55 cents.
    Its revenue rose 9% over the year earlier to $1.39 billion.
    The company also reiterated its adjusted profit forecast for
2025 at $2.40 to $2.50 per share.

 (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi
Majumdar)